ESR1 and breast cancer: The neoPEHP trial (NCT04858516) is looking into neoadjuvant treatment of unilateral, invasive ER+/HER2+ BC with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) and oral pyrotinib (400 mg po QD) for six cycles plus oral palbociclib (125 mg once a day for 21 days in a 4-week cycle) and oral exemestane.